A $6.4 billion accord for U.S. drug and device reviews is set to unravel just three months after taking effect as lawmakers squabble over budget cutbacks. Drug reviews, which rely heavily on fees paid by companies, may slow or halt in January because the FDA must receive certain funding from Congress before it can spend any of the industry money, said Karen Riley, an FDA spokeswoman.
Bloomberg